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Introduction. Malignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive soft tissue sarcomas associated with poor
prognosis,that most commonlyaﬀect patients aged 20 to 50 years, but have also been reported in children. There is little reported
in literature on these tumors in Africa. Materials and Methods. A search of the hospital pathology database between 1992 and
2008 revealed 333 nerve sheath tumors, of which 31 were MPNSTs. Four representative case reports are presented. Discussion.
MNPSTs have rarely been reported from sub-Saharan Africa; in this study, they constituted 9.3% of all nerve sheath tumors. The
trunk (42%) and limbs (45%) were the most frequently aﬀected anatomical sites. Late presentation of malignant lesions in this
environment is exempliﬁed by the four case presentations patients. Conclusions. This report conﬁrms observations from studies
onMPNSTs from otherenvironments.Anatomicallycentrally located MPNSTsmayhavea higherincidence in sub-SaharanAfrica
than in the West. Because NF1-associated MPNSTs are diﬃcult to diagnose clinically, and bec a u s es u r g e r yi st h eo n l ym o d eo f
therapy that oﬀers a complete cure, a lifetime follow-up is important, as this would enable diagnosis of early lesions amenable to
surgical extirpation.
1.Introduction
Benign and malignant peripheral nerve sheath tumors may
occur sporadically or in conjunction with neuroﬁbromatosis
type 1 [1]. Malignant peripheral nerve sheath tumors
(MPNSTs) are rare, aggressive soft tissue sarcomas that
either arise from a peripheral nerve or show nerve sheath
diﬀerentiation. Up to 11% may arise secondary to radiation
therapy,withlatenciesof20to40years [2].MPNSTsaccount
for 10% of all soft tissue sarcomas and are associated with
a high risk of metastases and local recurrence, resulting in
poor prognosis. They metastasize to the lungs, liver, brain,
bone, regional lymph nodes, and skin, amongst other organs
[1, 3]. MPNSTs most commonly aﬀect patients aged 20 to 50
years, but have also been reported in children [4–6].
Approximately 50% of MPNST occur in patients with
neuroﬁbromatosistype1[7].MPNSTsreducethelifeexpect-
ancyofNF1patientsbyupto15years.PatientswithNf1have
an 8% to 13% lifetime risk of developing MPNST [8, 9].
Factors associated with the development of MPNSTs
include NF1 patients with many, extensive, or centrally
located plexiform neuroﬁbromas, as are nodular plexiform
tumors associated with large peripheral nerve sheaths and
extensive tumors involving the brachial, lumbar, or sacral
plexus. Microdeletions of the NF1 locus may also be
indicatorsofhighriskforMPNSTdevelopment[3,10].Most
NF1-associated MPNSTs arise within preexisting plexiform
neuroﬁbromas; patients with Nf1 therefore should be under
lifetime surveillance for the development of MPNST [10].
Rhabdomyosarcomas have also been reported to occur in
NF1 patients [11].
There is little reported in the literature on malignant
peripheral nerve sheath tumors in Africa [12–15]. Although
rare, some reports from the USA suggest a higher incidence
amongst Blacks than Caucasians [16]. There are no com-
parative data from sub-Saharan Africa. The authors sought
to ﬁnd the demographics of MPNSTs amongst sub-Saharan
Africans.2 ISRN Surgery
Table 1: Characteristics of patients with MPNST.
Sex Age (yrs) NF1 status Anatomic site
F2 2 N F 1 S i t e U n k n o w n
F 24 NF1 Retroperitoneum
M2 9 N F 1 N e c k
M3 6 S o l i t a r y L e g
M 38 Solitary Axilla
F6 4S o l i t a r y T h i g h
F 18 Solitary Forearm
M? S o l i t a r y A r m
F2 6 N F 1 C h e s t w a l l
M2 9 S o l i t a r y T h i g h
M3 0 N F 1 L e g
M 18 Solitary Hand
M2 2 N F 1 B a c k
F3 0 N F 1 N e c k
M2 2 N F 1 B a c k
M 38 Solitary Axilla
F3 8S o l i t a r y L e g
F2 6 N F 1 C h e s t w a l l
M 70 Solitary Back
F8 0 N F 1 B a c k
F2 5S o l i t a r y L e g
M 12 Solitary Back
F 36 Solitary Breast
M4 3 N F 1 S c a l p
F7 8S o l i t a r y N e c k
M1 0 N F 1 A r m
F8 N F 1 G l u t e a l
M 27 Solitary Back
M7 0 S o l i t a r y R e t r o p e r i t o n e u m
F2 5 N F 1 H a n d
F 29 NF1 Anterior abdominal wall
2.Materialsand Methods
Records on surgical specimens submitted for histological
examination to the hospital pathology department between
1992 and 2008 reported as peripheral nerve sheath tumors
were retrieved from the database. Clinical records of four
patients who presented to the authors’ hospital and were
found to have malignant peripheral nerve sheath tumors
were reviewed and are reported; these were not part of the
data from the pathology department. An Internet/PubMed
search of sub-Saharan published literature on MPNSTs was
made.
3.Results
There were a total of 333 peripheral nerve sheath tumors
diagnosed over the 16 years; 31 patients (15 females and 16
males) had a histological diagnosis of malignant peripheral
nerve sheath tumor (Table 1). Patients with MPNSTs had a
meanage of34 years (8to 80).The trunk, upperlimbs, lower
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Figure 1: Coronal CTScan showing large retroperitoneal tumor
extending and abutting the spinal cord. Abdominal contents are
compressed paracolic gutter.
limbs, and head and neck constituted 42%, 22.5%, 22.5%,
and 10%, respectively. In one patient (3%), the anatomic site
of origin was not indicated. Fifteen of the 31 patients (48%)
had neuroﬁbromatosis type 1 (NF1). Sixty percent of female
patients had NF1, while 40% of males had NF1 (Table 1).
The authors found only four papers from sub-Saharan
Africa that had reported MPNSTs [12–15].
4.Case Presentations
Case Report 1. A 21-year-old female patient with NF1 pre-
sented with lower limb pain and weakness for one year. She
also had a large abdominal mass associated with early satiety
and constipation for four months prior to presentation. She
was cachectic, with a weight of 42kg. A CT Scan showed an
extensive retroperitoneal tumor compressing the diaphragm
cranially, and ﬁlling the pelvic cavity, likely of paraspinal
origin (Figure 1). At surgery, a large fairly well-encapsulated
retroperitoneal tumor involving the nerve roots of L3, 4, and
5 was excised. The vertebral bodies of L4 and L5 had been
eroded, and an iliac crest bone strut was used to support the
L4 vertebral body. The tumor weighed 5.5kg. Histology was
reported as MPNST. Postoperatively, the patient’s symptoms
improved; she was able to eat well and ambulate.
Case Report 2. A 19-year-old female with NF1 presented
with a one-week history of left thigh pain and inability to
walk. She had multiple large bilateral upper limb masses
(bilateral axillary and right arm) that were associated
with pain and paraesthesiae (Figure 2). A skeletal survey
(whole body radiographs) revealed a pathological fracture
of the neck of left femur (Figure 3), as well as extensive
bone lesions involving the right femur, both humeri and
lumbar vertebrae. The three large masses were excised, with
histopathological results revealing a malignant MPNST in
the right forearm tumor and severe dysplasia in the rightISRN Surgery 3
Figure 2: Pre-operative picture of case report 2: note bilateral
axillary tumors in addition to large mass over right arm.
Figure 3: Pathological fracture of the left hip, with contralateral
osteolytic lesions.
axillary mass. The left axillary mass was a benign nerve
sheath tumor.
Thefemurfracturewasﬁxed;biopsiesrevealedmetastatic
MPNST. Subsequently, while still in the hospital, she devel-
oped bilateral lower limb weakness and stumbled and fell
while walking. She sustained pathological fractures of the
4th and 5th lumbar vertebra and the right humerus. After
operative ﬁxation of the humeral fracture, she was referred
elsewhere for chemoirradiation and got lost to followup.
Case Report 3. A 35-year-old male presented with an
ulcerated, pedunculated mass on the left thigh for a period
of 5 years (Figure 4). He had no stigmata of NF1. After a
biopsy showing it to be a malignant peripheral nerve sheath
tumor,awideexcisionwasperformed;negativemargins were
conﬁrmed at histology.
Case Report 4. A 21-year-old male with NF1 presented with
a large painful, ulcerated mass involving the proximal two-
thirdsoftheleftleg(Figure 5).Hehadhadthemass formany
years, but had noted a rapid increase in the size of the tumor
in the ﬁve months prior to presentation. A clinical diagnosis
of MPNST was made. He had no evidence of metastases,
Figure 4: Preoperative picture of third case report: solitary
malignant peripheral nerve sheath tumor.
Figure 5: Malignant peripheral nerve sheath tumor of the left leg.
and an above-knee amputation was performed. Histological
examination revealed MPNST (Figures 6 and 7).
The patient was ambulant with crutches 24 hours after
surgery, with minimal pain.
5.Discussion
Late presentation of patients with advanced malignancies
is not uncommon in sub-Saharan Africa. Of the four
representative patients, only one had a surgically curable
lesion, even though he presented late with an ulcerated
lesion; a second potentially curable lesion was the fourth
patient who underwent an above-knee amputation. One of
the other two patients had extensive bony lesions, resulting
in a number of pathological fractures: femoral, humeral
fracture, and lumbar vertebral fractures. The quality of
life of the ﬁrst and third patients improved signiﬁcantly
postoperatively.
The rarity of MPNSTs in the sub-Saharan population
is attested to by the few reports and low numbers from
the region [12–15]. Odebode et al. in a clinicopathological
reviewcovering22years, found98patientswith nervesheath
tumors, of whom 3.1% had PMNSTs [13]. In Samaila and
Adewuyi’s review of 382 cutaneous malignancies, only three
were MPNSTs, representing 0.8% of the tumors [14]. Two
large studies from Kenya, one on neural tumors of the head4 ISRN Surgery
Figure 6:Photomicrographshowingherringbonepattern ofmalig-
nant spindle cell tumor with mitosis (arrows) (hematoxylin and
eosin stained; magniﬁcation ×100).
Figure 7: High-magniﬁcation photomicrograph showing malig-
nant spindle cell tumor with frequent mitosis (arrows). Note
high cellularity and nuclear polymorphism (hematoxylin and eosin
stained; magniﬁcation ×400).
and neck, and another on sarcomas of the head and neck,
d i dn o tﬁ n da n yM P N S T s[ 17, 18], while Tenge et al., in
establishing a cancer registry of Western Kenya, did not
report any MPNSTs from a patient population of over 5000
with diﬀerent types of cancers [19]. Adeyemi et al. found
MPNSTs in 6.5% of all head and neck cancers in a Nigerian
institution—four of the ﬁve patients were females [15].
In the current study, 9.3% of histologically diagnosed
nerve sheath tumors were MPNST. One patient had a triton
tumor; MPNSTs with rhabdomyoblastic diﬀerentiation may
have a more aggressive clinical course than other MPNSTs
[20]. Sixty-one percent of patients were aged between 20 and
40 years, consistent with the reports of other authors [4],
while 15 (48%) of patients in the current study had NF1,
similar to other studies [7].
MPNSTs in other studies most commonly involve major
nerve trunks, such as the brachial plexus, sacral plexus, or
the sciatic nerve and often present with pain and motor
or sensory deﬁcits [1, 21]. However, though pain, neuro-
logical deﬁcits, and growing masses are the main clinical
indicators of malignancy, they are also presenting symptoms
in some patients with benign plexiform neuroﬁbromas,
making it diﬃcult to diﬀerentiate on clinical grounds only,
between malignant and benign lesions [7, 10, 22, 23]. In
the current study, the trunk was the commonest involved
anatomic site (42%), a ﬁnding reported in some studies
[24].
The MPNSTs in multiple bones in one patient were
either metachronous tumors or metastatic from the upper
extremity lesions. Pathological fractures from MPNSTs are
very rare but have been reported [25]. Sar and Eralp
proposed an aggressive therapy for spinal metastatic disease
[25]. In the current paper, the patient who sustained lumbar
vertebral pathological fractures/collapse, after stabilization
of the femoral and humeral fractures, was referred for
oncologic care.
Patients with MPNSTs may have a poorer prognosis
than those with sporadic tumors, because NF1-associated
MPNSTs tend to be centrally located, and therefore less
amenable to surgery [7]. Poor prognostic factors include
tumor size (greater than 5cm), local invasion, and histologic
grade. Good prognostic factors include duration of less than
6 months, clear surgical margins, and an age less than 30
years [26].
Aggressive wide resection (at least 10cm margins),
including limb amputation, is advocated for MPNST, as in
t h ef o u r t hc a s er e p o r t .W h i l et h i sm a yb ei m p o s s i b l ei n
anatomically centrally located sites, unfortunately, surgery
is the only modality of therapy that can achieve cure [22,
27, 28]. Limb-sparing excision with chemoradiotherapy in
combination or separately is increasingly favored. The role
of chemotherapy for MPNSTs is not yet deﬁned, although
a favorable response in both children and adults has been
reported [1, 7, 12, 22]. Local recurrence of MPNST is high,
even with multimodal therapy, reported to be between 30%
to 65% [27, 28].
While patients with NF1-associated MPNSTs presented
at an average age of 27 years, those with sporadic MPNSTs
had a mean age of 42 years, a ﬁnding consistent with other
reports that have shown NF1-associated MPNSTs present at
an earlier age [7, 23].
Retroperitoneal MPNSTs have a very poor prognosis,
because of an insidious onset, local invasiveness, and fre-
quently late diagnosis. Further,s u r g i c a le x c i s i o ni si n c o m -
plete, and chemotherapy and radiotherapy are reportedly
ineﬀective in retroperitoneal MPNSTs [24]. Patients often
succumb to systemic metastatic disease [29]. Surgical exci-
sion of the giant retroperitoneal peritoneal tumor in the
patient reported here was of immediate beneﬁt, improving
h e ra b i l i t yt oe a ta n dr e t a i nf o o d ,a sw e l la sa m b u l a t e ,a sw a s
the leg amputation for the fourth patient.
There was no diﬀerence in the incidence of centrally
located tumors between NF1-associated and sporadically
occurring MPNSTs in the current study. This high incidenceISRN Surgery 5
of nonextremity lesions in sub-Saharan Africa MPNSTs may
be equated with poor prognosis, resulting from incomplete
resections, recurrences, and deaths, especially in an envi-
ronment where other modalities of therapy are either
unavailable or unaﬀordable.
The ﬁnal outcomes of the 31 patients reported here
are unknown. Of the four representative case reports, two
returned for followup; the surgical margins in both patients
were considered adequate, and adjuvant therapy was consid-
ered unnecessary. The outcome of the two female patients
remainsunknownastheydidnotreturnafteroncologyrefer-
rals.Becausenegativesurgicalmarginswerenotachievablein
the two patients and because of extensive metastases in one,
it is likely that they may have succumbed to the disease and
died. Oncologic services in Kenya remain either diﬃcult to
access because of large volumes of patients awaiting therapy
inpublicinstitutionsorinaccessiblebecauseofcostinprivate
hospitals.
6.Conclusions
Malignant peripheral nerve sheath tumors are rare malig-
nancies that have been infrequently reported from sub-
Saharan Africa. This clinicopathological report conﬁrms
observations from studies on MPNSTs from other envi-
ronments: they are rare and 48% occurred in NF1
patients, in whom they occur at a younger mean age (27
years), in comparison to patients with solitary MPNSTs
(42 years).
Unlike most Western studies, however, there was no
diﬀerence in the incidence of centrally located MPNSTs
(which have a poor prognosis), between NF1-associated
MPNSTs and solitary MPNSTs.
Because malignant lesions in NF1 patients are diﬃcult
to diagnose clinically and because surgery is the only mode
of therapy that oﬀers a complete cure, a lifetime followup
is important, as this would enable diagnosis of early lesions
amenable to surgical extirpation.
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